Results 191 to 200 of about 38,006 (217)

Tirzepatide and SGLT2 Inhibitors for Heart Failure With Preserved Ejection Fraction and Obesity: Entering a New Cardiometabolic Therapeutic Era. [PDF]

Endocrinol Diabetes Metab
Mohamed ZI, Shidane AA, Abdiasis AM, Hussein MH, Ibrahim AO, Abdi AA, Hashi KI, Mohamud MA, Mohamed AJ.   +8 more
europepmc   +1 more source

Differential uptake of SGLT2 inhibitors in England following heart failure guideline expansion: a controlled interrupted time series analysis. [PDF]

BMJ Open
Aladul MI, Hijazeen RA, Al-Shammaa ZM.
europepmc   +1 more source

Impact of SGLT2 Inhibitors on Glomerular Filtration in Type 1 Diabetes.

J Clin Endocrinol Metab
Holliday MW, Navaneethan SD.
europepmc   +1 more source

eGFR- and Potassium-Guided Stewardship of SGLT2 Inhibitors and Finerenone in Albuminuric Chronic Kidney Disease Associated with Type 2 Diabetes. [PDF]

Diabetes Metab Syndr Obes
Su C, Li X, Wang S, Liu D.
europepmc   +1 more source

SGLT2 Inhibitors and Liver Cirrhosis: Hype or Hope? [PDF]

Life (Basel)
Brusnic O, Onisor DM, Boicean A, Porr C, Sofonea FD, Anderco P, Ichim C.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Emergence of SGLT2 Inhibitors as Powerful Antioxidants in Human Diseases

Antioxidants, 2021
Wen-Chin Lee, Kai-Fan Tsai
exaly  

Use of SGLT2 inhibitors and occurrence of noninfectious respiratory disorders: a meta-analysis of large randomized trials of SGLT2 inhibitors

Endocrine, 2021
Mei Qiu, Shu-Yan Liu, Liangliang Ding
exaly